盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Anlotinib Hydrochloride Capsules in the treatment of advanced non-small cell lung cancer.Methods A total of 86 patients with advanced non-small cell lung cancer who admitted to Bao′an District People′s Hospital of Shenzhen City from May 2016 to May 2018 were selected as the research objects and divided into the control group and the study group by random number table method,with 43 cases in each group.The control group was treated with placebo,while the study group was treated with Anlotinib Hydrochloride Capsules.The time of tumor progression or death (PFS),total survival time (OS),clinical effect and total incidence of adverse events (AEs) were compared between the two groups.Results The PFS and OS in the study group were longer than those in the control group,and the differences were statistically significant (P＜0.05).The clinical effect of the study group was better than that of the control group,and the difference was statistically significant (P＜0.05).There was no statistically significant difference in total incidence of AEs between the two groups (P＞0.05).Conclusion The clinical effect of Anlotinib Hydrochloride Capsules in the treatment of advanced non-small cell lung cancer is better,it can effectively extend the patients′ progression-free survival time,and has good tolerance,but in terms of safety,evaluation of the scope of the study still needs to be further expanded.

Key words： Antinib Hydrochloride Capsules Advanced Non-small cell lung cancer Clinical effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEI Zhao-guang
	CHENG Yan-lin
	WANG Chang-qing
	HE Ai-jun

Cite this article:

WEI Zhao-guang,CHENG Yan-lin,WANG Chang-qing, et al. Effect of Antinib Hydrochloride Capsules in the treatment of advanced non-small cell lung cancer[J]. 中国当代医药, 2020, 27(34): 111-113.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I34/111

[1]	陈惠，王汉萍，张力，等.盐酸埃克替尼一线治疗晚期非小细胞肺癌的疗效与安全性[J].中华内科杂志，2017，56（1）：39-43.
[2]	丁传彪.埃克替尼在晚期非小细胞肺癌靶向治疗中的疗效观察[J].中国生化药物杂志，2017，37（11）：111-112.
[3]	张洪波，王建东.埃克替尼治疗晚期非小细胞肺癌复发的临床疗效及安全性[J].航空航天医学杂志，2017，28（6）：722-724.
[4]	谢占强，余丽双，程可洛，等.对比吉非替尼和埃克替尼靶向治疗晚期非小细胞肺癌的临床效果[J].齐齐哈尔医学院学报，2017，38（23）：2761-2762.
[5]	杨明花.阿帕替尼针对二线治疗失败的晚期非小细胞肺癌的近期疗效观察[J].临床荟萃，2017，32（10）：877-880.
[6]	彭积贵，吴岩妹，陈辉，等.盐酸埃克替尼对老年晚期非小细胞肺癌患者生存质量及血清肿瘤标志物的影响[J].中国现代医药杂志，2017，19（3）：18-20.
[7]	李群，刘卓环，张军科.盐酸厄洛替尼片治疗晚期非小细胞肺癌的临床效果观察[J].深圳中西医结合杂志，2017，27（13）：130-132.
[8]	周磊，邵燕儿，朱泽浩，等.华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究[J].中国全科医学，2018，21（9）：1047-1052.
[9]	刘立芳，谷蕾，刘利谨，等.慈丹胶囊联合厄洛替尼治疗晚期非小细胞肺癌的临床研究[J].现代药物与临床，2017，32（11）：2198-2202.
[10]	王晓莉，王财，殷麟.吉非替尼联合平消胶囊治疗中晚期非小细胞肺癌临床疗效观察[J].中药材，2017，40（3）：724-726.
[11]	纪春东，于秀芹，赖永新.盐酸埃克替尼治疗EGFR 突变状态明确的晚期非小细胞肺癌的临床观察[J].河北医学，2017，23（1）：100-102.
[12]	李蓉，谭小武.安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评估[J].现代医药卫生，2019，35（18）：2815-2817.
[13]	辛涛，金发光，刘伟，等.盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究[J].中华肺部疾病杂志（电子版），2018，11（5）：559-562.
[14]	范丽敬，陈学军，云游，等.低剂量CT 灌注成像对盐酸安罗替尼治疗肺癌疗效的早期评估[J].实用放射学杂志，2019，35（6）：977-980.
[15]	刘楠，吴秀伟，李烦繁，等.安罗替尼三线及以上治疗晚期非小细胞肺癌近期疗效和生命质量分析[J].国际肿瘤学杂志，2019，46（3）：147-152.